RNA-directed RNA polymerase · SINGLE PROTEIN · Hepacivirus hominis
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14RNA-directed RNA polymerase shows approved-linked disease relevance led by chronic hepatitis C virus infection. 5 more disease programs remain visible in the same review block. 18 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O39930. Start with chronic hepatitis C virus infection, then reuse UniProt O39930 as the stable protein anchor across project notes and exports.
Start with chronic hepatitis C virus infection, then reuse UniProt O39930 as the stable protein anchor across project notes and exports.
RNA-directed RNA polymerase shows approved-linked disease relevance led by chronic hepatitis C virus infection. 5 more disease programs remain visible in the same review block. 18 linked drugs remain visible in the same block.
Start review with chronic hepatitis C virus infection because it currently carries approved-linked support. Linked drugs include ABT-072, ADAFOSBUVIR, BALAPIRAVIR, BECLABUVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyRNA-directed RNA polymerase
Review this target as RNA-directed RNA polymerase, mapped to UniProt O39930. Sequence length is 591 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RNA-directed RNA polymerase as ChEMBL target CHEMBL4296320, mapped to UniProt O39930. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether RNA-directed RNA polymerase is the right protein anchor across sources, using UniProt O39930 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic hepatitis C virus infection is currently framed as approved-linked support. It currently carries 18 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | RNA-directed RNA polymerase |
| Target Type | SINGLE PROTEIN |
| Organism | Hepacivirus hominis |
| UniProt | O39930 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | RNA-directed RNA polymerase |
| UniProt Accession | O39930 |
| Component Type | Protein |
| Sequence Length | 591 aa |
RNA-directed RNA polymerase
Review this target as RNA-directed RNA polymerase, mapped to UniProt O39930. Sequence length is 591 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
RNA-directed RNA polymerase shows approved-linked disease relevance led by chronic hepatitis C virus infection. 5 more disease programs remain visible in the same review block.
Start review with chronic hepatitis C virus infection because it currently carries approved-linked support. Linked drugs include ABT-072, ADAFOSBUVIR, BALAPIRAVIR, BECLABUVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3955887 | 9.52 | EC50 | 0.3 | Preclinical |
| CHEMBL3961836 | 9.52 | EC50 | 0.3 | Preclinical |
| CHEMBL379613 | 9.4 | IC50 | 0.4 | Preclinical |
| CHEMBL3961240 | 9.4 | EC50 | 0.4 | Preclinical |
| CHEMBL179673 | 9.3 | EC50 | 0.5 | Preclinical |
| CHEMBL179970 | 9.3 | EC50 | 0.5 | Preclinical |
| CHEMBL4641600 | 9.3 | EC50 | 0.5 | Preclinical |
| CHEMBL4645241 | 9.3 | EC50 | 0.5 | Preclinical |
| CHEMBL361156 | 9.22 | EC50 | 0.6 | Preclinical |
| CHEMBL4644026 | 9.22 | EC50 | 0.6 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 150 | 1,197 | 6.4 |
| assay format | 63 | 179 | 6.8 |
| cell-based format | 45 | 154 | 7.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 7 | 17 | 5.5 |
| cell-based format | 7 | 31 | 6.1 |